Effects of raloxifene on normal breast tissue from premenopausal women.
The objective of this study was to evaluate the effects of raloxifene on normal breast tissue. A randomized, double-blind study was carried out in 30 ovulatory, premenopausal women of 18-40 years of age, who had been diagnosed with fibroadenoma of the breast. The patients were divided into two groups: Group A (placebo, n = 16) and Group B (raloxifene 60 mg, n = 14). The medication was given for 22 days, beginning on the first day of the menstrual cycle. An excisional biopsy was carried out on the 23rd day during which a sample of normal breast tissue was collected to evaluate the presence of the proliferating cell marker Ki-67. Student's t-test was used for the statistical analysis of data (p < 0.05). Mean percentage of stained nuclei in groups A and B was 10.96 +/- 1.27 and 1.21 +/- 0.26, respectively (p < 0.001). Raloxifene significantly reduced the proliferative activity of normal breast tissue in premenopausal women.
da Silva
Benedito Borges
BB
Department of Gynecology, Federal University of Piauí, Teresina, Piauí, Brazil. beneditoborges@globo.com
Lopes
Ione Maria Ribeiro Soares
IM
Gebrim
Luiz Henrique
LH
D000328:Adult; D001940:Breast / Q000187:drug effects* / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism / Q000517:prevention & control*; D002455:Cell Division / Q000187:drug effects; D004311:Double-Blind Method; D004848:Epithelium / Q000187:drug effects; D005260:Female; D018226:Fibroadenoma / Q000378:metabolism / Q000517:prevention & control*; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008875:Middle Aged; D017697:Premenopause; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
D019394:Ki-67 Antigen; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride